Aquestive Therapeutics stock slipped about 4% today, even though the headline from Q2 is more about balance sheet breathing room than a collapse in the story. The company ended the quarter with US$98.5m in cash and reaffirmed full year 2026 guidance for revenue in the US$46m to US$50m range and a non GAAP adjusted EBITDA loss of US$35m to US$30m.
For a small biopharma stock that trades on belief in future products, that mix of liquidity, steady guidance and ongoing losses is what is really driving the sentiment tug of war you are seeing in the share price.
Love the liquidity buffer at Aquestive Therapeutics but concerned about the ongoing adjusted EBITDA losses and cash burn risk? Take a look at our hand picked 85 resilient stocks with low risk scores if you want examples of companies that pair balance sheet strength with more measured loss profiles.
Q2 2026 Earnings Summary
- Revenue (Q2 2026 vs. Q2 2025): US$14.446m vs. US$10.003m (change reflects higher reported revenue year on year)
- Net Loss (Q2 2026 vs. Q2 2025): US$8.057m loss vs. US$13.548m loss (loss narrowed year on year)
- Basic EPS (Q2 2026 vs. Q2 2025): US$0.065712 loss per share vs. US$0.136398 loss per share (loss per share narrowed year on year)
- Trailing Twelve Month Revenue (TTM to Q1 2026 vs. TTM to Q1 2025): US$50.271m vs. US$54.228m (change reflects lower reported TTM revenue)
Prefer clean, visual charts over a dense wall of numbers and footnotes? See how Aquestive Therapeutics stacks up with a full view of its valuation profile in our company report for Aquestive Therapeutics.
Anaphylm Milestones Move Forward as Cash Holds Up
Bulls on Aquestive Therapeutics argue that Anaphylm can shift epinephrine treatment toward a convenient, needle free oral film, provided execution on regulators and launch prep stays on track. Q2 results give concrete proof points on that front. Management confirms all FDA Complete Response Letter requests are addressed and that the New Drug Application resubmission will be filed before the end of Q3 2026. Human factors issues flagged earlier now look materially reduced, with far fewer pouch opening and placement errors in the validation work. Pharmacokinetic and pharmacodynamic data, including the “misadministration” scenario, still meet FDA referenced exposure thresholds and show rapid physiological responses.
On the financial side, US$98.5m of cash and reaffirmed 2026 revenue and adjusted EBITDA loss guidance show the current plan is intact ahead of that regulatory decision. For the bullish view, these are key milestones hit rather than just promises repeated.
Compare that operational momentum with how the street is reacting to a share price that fell 4.08% after the release. See the consensus price target analysis for Aquestive Therapeutics to check whether analysts think Aquestive Therapeutics is on track or getting ahead of itself.Aquestive bears focus on missed de risking milestones
The core bearish claim on Aquestive Therapeutics is that execution and funding risks stay high until Anaphylm is fully de risked and the business is less dependent on one late stage asset. This quarter does not really move that concern off the table. Management confirms an Anaphylm NDA resubmission by the end of Q3 2026, yet there is still no FDA acceptance letter, no assigned review clock and no visibility on labeling or post marketing requirements. Those are the concrete milestones bears wanted to see progress toward. Financially, guidance for a US$35m to US$30m non GAAP adjusted EBITDA loss and ongoing net losses keeps the financing overhang alive, even with US$98.5m of cash and structured capital from Oaktree and RTW. The 4.08% share price fall after earnings suggests the market is still wary that key risk markers remain unresolved.
After a 4.08% share price fall and ongoing losses, review whether these concerns are isolated by reading our risk analysis for Aquestive Therapeutics which shows 4 important warning signs.Stay Ahead With Simply Wall St
If the mix of Anaphylm milestones, cash of US$98.5m and ongoing losses at Aquestive Therapeutics has your attention, register for free with Simply Wall St and add the stock to your Watchlist to track price against fair value and wait for an entry point that fits your plan. Once you decide to take a position, keep control of your next moves with the Portfolio Command Center that focuses your alerts on the most important developments instead of day to day noise. For long term context on Aquestive Therapeutics and similar stocks, join the Community to compare your thinking with other investors and spot shifts in sentiment early. That combination helps you surface potential catalysts and risks sooner so you can react before the wider market catches up.
Seeking Alternatives Beyond Aquestive Therapeutics
Fresh ideas often move first while the crowd watches. Spot potential breakout momentum, before under the radar stories get caught flying or dropping out of reach. Act now.
- Scan for smaller companies already turning AI momentum into real profits by reviewing the curated list in 70 profitable AI stocks that aren't just burning cash before the best entry points slip away.
- Zero in on sturdy balance sheets and steady fundamentals with the hand picked list of solid balance sheet and fundamentals stocks (49 results) so you are not chasing strength after prices start running.
- Track income ideas that aim to keep portfolios funded through thick and thin by checking the carefully filtered 9 dividend fortresses while yields are still holding up.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com